$147 Million is the total value of Knoll Capital Management, LLC's 31 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 3.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $73,496,000 | +31.8% | 857,494 | 0.0% | 50.11% | +9.7% | |
| APLT | Buy | Applied Therapeutics Inc | $18,751,000 | +22.9% | 851,551 | +15.9% | 12.78% | +2.2% |
| EIGR | Buy | Eiger Biopharmaceuticals Inc | $8,532,000 | +76.1% | 694,232 | +16.6% | 5.82% | +46.5% |
| CRBP | Corbus Pharmaceuticals HLDGS | $6,307,000 | -30.6% | 5,045,870 | 0.0% | 4.30% | -42.2% | |
| ORGS | Orgenesis, Inc. | $5,924,000 | -10.7% | 1,316,364 | 0.0% | 4.04% | -25.7% | |
| ABEO | Abeona Therapeutics Inc | $4,490,000 | +53.9% | 2,859,767 | 0.0% | 3.06% | +28.1% | |
| ALDX | Aldeyra Therapeutics Inc | $3,906,000 | -7.4% | 569,405 | 0.0% | 2.66% | -23.0% | |
| AVXL | Buy | Anavex Life Sciences Corp | $3,622,000 | +28.2% | 670,789 | +8.1% | 2.47% | +6.7% |
| BX | Blackstone Group LP | $2,592,000 | +24.1% | 40,000 | 0.0% | 1.77% | +3.3% | |
| XCUR | Exicure Inc | $2,262,000 | +1.2% | 1,277,777 | 0.0% | 1.54% | -15.8% | |
| LUMN | Lumen Technologies Inc | $2,145,000 | -3.4% | 220,000 | 0.0% | 1.46% | -19.6% | |
| ENTX | Entera Bio Ltd | $1,881,000 | -12.9% | 1,741,363 | 0.0% | 1.28% | -27.5% | |
| DOW | Dow Inc | $1,665,000 | +17.6% | 30,000 | 0.0% | 1.14% | -2.2% | |
| CTVA | Corteva Inc | $1,162,000 | +34.5% | 30,000 | 0.0% | 0.79% | +11.9% | |
| MTEM | Molecular Templates | $1,070,000 | -14.0% | 113,905 | 0.0% | 0.73% | -28.5% | |
| DD | Dupont de Nemours Inc | $1,067,000 | +28.2% | 15,000 | 0.0% | 0.73% | +6.6% | |
| SNGX | Soligenix Inc. | $1,008,000 | -28.5% | 787,830 | 0.0% | 0.69% | -40.5% | |
| BTAI | BioXCel Therapeutics Inc | $924,000 | +6.6% | 20,000 | 0.0% | 0.63% | -11.3% | |
| SA | SEABRIDGE GOLD INC | $674,000 | +12.1% | 32,000 | 0.0% | 0.46% | -6.7% | |
| MMX | MAVERIX METALS INC | $628,000 | +6.3% | 115,000 | 0.0% | 0.43% | -11.6% | |
| ALT | New | Altimmune Inc | $564,000 | – | 50,000 | +100.0% | 0.38% | – |
| OR | OSISKO GOLD ROYALTIES LTD | $551,000 | +11.1% | 190,000 | 0.0% | 0.38% | -7.4% | |
| AEM | AGNICO EAGLE MINES LTD | $487,000 | -11.3% | 6,900 | 0.0% | 0.33% | -26.2% | |
| FNV | FRANCO NEV CORP | $470,000 | -10.1% | 3,750 | 0.0% | 0.32% | -25.4% | |
| EQX | EQUINOX GOLD CORP | $470,000 | -11.8% | 45,500 | 0.0% | 0.32% | -26.8% | |
| KL | KIRKLAND LAKE GOLD LTD | $444,000 | -15.3% | 10,750 | 0.0% | 0.30% | -29.4% | |
| FSM | FORTUNA SILVER MINES INC | $360,000 | +29.5% | 43,700 | 0.0% | 0.24% | +7.5% | |
| MAG | MAG SILVER CORP | $355,000 | +26.3% | 17,300 | 0.0% | 0.24% | +5.2% | |
| SILV | SILVERCREST METALS INC | $347,000 | +31.9% | 31,000 | 0.0% | 0.24% | +9.7% | |
| PAAS | PAN AMERN SILVER CORP | $283,000 | +7.2% | 8,200 | 0.0% | 0.19% | -10.6% | |
| SVM | SILVERCORP METALS INC | $244,000 | -7.6% | 36,500 | 0.0% | 0.17% | -23.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.